Panel seeks new drug pricing rules


In a move to promote innovation, a government panel on regulatory reforms has called for revising the existing rules on setting official prices for drugs and medical instruments.

The panel proposed Thursday placing higher prices on more innovative products to stimulate research and development. Domestic producers tend to first launch newly developed drugs and medical devices overseas, where they can sell innovative products at higher prices than at home, industry sources said.

Under the circumstances, there are concerns that patients in Japan are missing opportunities to benefit from innovation.